NERVGEN PHARMA CORP (NGEN.CA) Stock Price, Forecast & Analysis
TSX-V:NGEN • CA64082X2032
NGEN.CA Key Statistics, Chart & Performance
The current stock price of NGEN.CA is 5.65 CAD. In the past month the price decreased by -13.34%. In the past year, price increased by 104.71%.
NGEN.CA Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to NGEN.CA. When comparing the yearly performance of all stocks, NGEN.CA is one of the better performing stocks in the market, outperforming 76.54% of all stocks.
NGEN.CA Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to NGEN.CA. NGEN.CA has a bad profitability rating. Also its financial health evaluation is rather negative.
NGEN.CA Financial Highlights
Over the last trailing twelve months NGEN.CA reported a non-GAAP Earnings per Share(EPS) of -0.38. The EPS increased by 2.11% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -197.42% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
NGEN.CA Forecast & Estimates
8 analysts have analysed NGEN.CA and the average price target is 7.75 CAD. This implies a price increase of 37.2% is expected in the next year compared to the current price of 5.65.
NGEN.CA Ownership
NGEN.CA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| BHC | BAUSCH HEALTH COS INC | 1.41 | 3.071B | ||
| CRON | CRONOS GROUP INC | 38.2 | 1.422B | ||
| TLRY | TILRAY BRANDS INC | N/A | 1.264B | ||
| DHT-UN | DRI HEALTHCARE TRUST | 7.3 | 921.872M | ||
| WEED | CANOPY GROWTH CORP | N/A | 650.504M | ||
| GUD | KNIGHT THERAPEUTICS INC | 132.99 | 629.897M | ||
| CPH | CIPHER PHARMACEUTICALS INC | 28.53 | 389.565M | ||
| TSND | TERRASCEND CORP | N/A | 337.883M | ||
| HITI | HIGH TIDE INC | 26.33 | 308.669M |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the TSX Venture Exchange Exchange | Find stocks with similar TA and Setup ratings on the Canadian exchanges | Find stocks with similar Fundamental rating on the Canadian exchanges | Find the competitors with the best technical ratings on the Canadian exchanges | Find the competitors with the best fundamentals on the Canadian exchanges | Find the competitors with the best valuation on the Canadian exchanges | Find the competitors with the best dividend on the Canadian exchanges | Find the competitors with the best analyst ratings on the Canadian exchanges
About NGEN.CA
Company Profile
NervGen Pharma Corp. operates as a clinical stage biotech company. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2019-03-13. The firm is engaged in developing treatments to promote nervous system repair in the settings of neurotrauma and neurologic disease. NVG-291 is in a Phase 1b/2a clinical trial in spinal cord injury and has undertaken preclinical evaluation of a new development candidate, NVG-300, in models of ischemic stroke, amyotrophic lateral sclerosis (ALS) and spinal cord injury (SCI). Its NVG-291 is a therapeutic peptide targeting nervous system repair.
Company Info
NERVGEN PHARMA CORP
Suite 1703 - 595 Burrard Street
Vancouver BRITISH COLUMBIA V7X 1J1 CA
CEO: Paul Brennan
Employees: 7
Phone: 16047225361
NERVGEN PHARMA CORP / NGEN.CA FAQ
What does NERVGEN PHARMA CORP do?
NervGen Pharma Corp. operates as a clinical stage biotech company. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2019-03-13. The firm is engaged in developing treatments to promote nervous system repair in the settings of neurotrauma and neurologic disease. NVG-291 is in a Phase 1b/2a clinical trial in spinal cord injury and has undertaken preclinical evaluation of a new development candidate, NVG-300, in models of ischemic stroke, amyotrophic lateral sclerosis (ALS) and spinal cord injury (SCI). Its NVG-291 is a therapeutic peptide targeting nervous system repair.
What is the stock price of NERVGEN PHARMA CORP today?
The current stock price of NGEN.CA is 5.65 CAD. The price decreased by -1.57% in the last trading session.
Does NGEN stock pay dividends?
NGEN.CA does not pay a dividend.
How is the ChartMill rating for NERVGEN PHARMA CORP?
NGEN.CA has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
How is the market expecting NGEN stock to perform?
8 analysts have analysed NGEN.CA and the average price target is 7.75 CAD. This implies a price increase of 37.2% is expected in the next year compared to the current price of 5.65.
What is the next earnings date for NGEN stock?
NERVGEN PHARMA CORP (NGEN.CA) will report earnings on 2026-04-01.